Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
rationeel schreef op 28 februari 2020 14:21 :
[...]
Hier is de aanleiding voor het pb:
today announces that the Company will... present... first preclinical results on OX401,... its... next-generation... PARP inhibitor (PARPi),... during a poster session at the... ESMO-TAT1 Congress 2020 ...dedicated to the research on targeted cancer therapies, to be held in... Paris, France,... on... March 2-4, 2020...
Daar ontmoeten ze elkaar, en kunnen misschien zaken doen;)
Bedankt, maar zoals ik al zei vind ik het knap lastig al die Engelse (technische) teksten te lezen. Ach ja, als het paar positief is. Welke bedrijven noemde jij in het Corona-verhaal? Niet dat ik ze kopen wil (heb mijn neus al een paar keer flink gestoten), maar wil wel meekijken.
20% er af vandaag :-( Met dit aandeel komt het voor mij nooit meer goed.
Paris (France), February 27, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces the postponement of the publication of its 2019 full-year results until April 17, 2020, after the close of trading. Indeed, due to the constraints imposed by the current context, the meeting of the Board of Directors to close the accounts, which was scheduled for March 31, 2020, has been postponed to April 17, 2020. As a result, the Combined General Meeting, initially scheduled to be held on May 13, 2020, is postponed to May 29, 2020.
Het wordt tijd dat dit aandeel ook eens een sprong voorwaarts gaat maken zoals sommige aandelen dat ook doen in deze Corona-tijd ;-)
Onxeo reçoit 6,6 M$ en contrepartie de la concession de droits exclusifs additionnels sur belinostat à Acrotech Biopharma.www.boursier.com/actions/actualites/n...
Boven 0,5306 blijven dan is het aandeel uit het dalende kanaal.
Onxeo : to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC > This transaction completes Onxeo’s strategic transition to a company solely focused on DNA Damage Response (DDR) activities in oncology > $6.6m received from Acrotech extends Onxeo’s cash runway into Q2 2021 and supports Company’s DDR-related programs
INVITATION To mark the publication of its 2019 Full Year Results, the management team of Onxeo is pleased to invite you to a conference call on: Friday, April 17, 2020 at 6:15 pm CEST followed by a Q&A session. The call will be accessible via the below conference call details: France: +33 1 72 72 74 03 United States: +1 646 7224 916 United Kingdom: +44 20 71943 759 Denmark: +458 23 33 187 PIN code: 47169541# You can also follow the slideshow presentation on the web:www.anywhereconference.com?Conference...
rationeel schreef op 15 april 2020 15:14 :
Boven 0,5306 blijven dan is het aandeel uit het dalende kanaal.
Net aan gelukt ;-) Kom nu maar op. Lang genoeg gewacht.
Bijna ob. Prettig wanneer het aandeel vervolgens bij het retracen boven de 51,09...46,86 blijft.
rationeel schreef op 17 april 2020 14:32 :
Bijna ob.
Prettig wanneer het aandeel vervolgens bij het retracen boven de 51,09...46,86 blijft.
Ver eronder !
50% retracement op de dag...0,4575. 0,514 bovenkant neerwaartse kanaal. Zit hij nu weer tegenaan:( Indien het aandeel boven de 0,4575 de nieuwe bodem zet, dan kan deze weerstand overwonnen worden. Houd goede moed:)
Paris (France), May 19, 2020 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced the presentation of preclinical data supporting the differentiated ability of AsiDNA™, its first-in-class DNA Damage Response (DDR) inhibitor, to reverse resistance to PARP inhibitors (PARPi) by preventing death-tolerant cells (DTC) regrowth. These promising results will be presented in an e-posters session during the American Association for Cancer Research (AACR) annual meeting which, given the COVID-19 context, will be held virtually on June 22-24, 2020. Françoise Bono, PhD, Chief Scientific Officer of Onxeo, commented: "We continue to strengthen our understanding of AsiDNA™'s unique mechanism of action and have generated new data demonstrating its ability to specifically target drug-tolerant or persistent tumor cells that result in resistance to targeted therapies, and in particular, as we are demonstrating for the first time in this study, resistance to PARP inhibitors. We are delighted to be able to present at this prestigious oncology-focused meeting this new study on the effect of AsiDNA™ on these persistent cells when combined with PARP inhibitors. These results add to AsiDNA™'s strong preclinical file, reinforce the legitimacy of its current development in the clinical setting and confirm its interest and value in our Company's portfolio.” These new data show for the first time that PARPi resistance can be caused by drug-tolerant cells, and that the addition of AsiDNA™ to PARP inhibitors prevents the regrowth of these cells, thereby completely and irreversibly abolishing the emergence of resistance in ovarian tumor cells. The results from this study are extremely encouraging for the upcoming Phase 1b/2 REVocan study, combining AsiDNA™ with niraparib in the clinical setting in recurrent ovarian cancer, which is expected to start in the second half of 2020. These data clearly reinforce AsiDNA™'s interest in the fight against resistance, which is the main challenge in cancer treatment today. Session: PO.ET03.04 - Mechanisms of sensitivity and resistance to DNA damage repair targeting Date/ Time: June 22, 2020 - 9:00 AM - 6:00 PM (U.S. Eastern Daylight Time -EDT) E-poster: 4078 / 8 Click on this link to read the abstract: Acquired resistance to PARP inhibitors evolves from drug-tolerant persister cells vulnerable to AsiDNA™. About Onxeo Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline. AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA™ in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments. OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.www.onxeo.com
Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation The press release in PDF Paris (France), May 27, 2020 – 8:45 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced the publication of an initiation report by Bryan Garnier & Co, a leading independent European financial services company specialized in research, execution and advisory services. Bryan Garnier & Co. will now follow Onxeo's share price on the Euronext Paris stock exchange* and values the Company at 1.22 euro per share*. For more information: www.bryangarnier.com ou drayot@bryangarnier.com (Head of Corporate Sales). * This information does not constitute an offer to sell or subscribe, or the solicitation of an order to buy or subscribe for securities in France, Europe, the US or any other country. Onxeo and Bryan Garnier & Co have agreed on a service for the production and distribution of financial analyses. About Bryan Garnier & Co Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo and Reykjavik as well as New York and Palo Alto. The firm is a member of the London Stock Exchange. About Onxeo Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline. AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA™ in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments. OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.www.onxeo.com
Zeer mooie stijging vandaag. Wat te doen? Zal het verder stijgen of komt er weer een omslagpunt? Ik sta nog lang niet Breakeven.
Ik ook niet. Maar nu heb ik toch spijt niet op die laagste prijs te hebben bijgekocht. Is de stijging omdat Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation, of omgekeerd, omdat ze zo goed gaan, heeft Bryan Garnier & Co zin om te gaan volgen en koop aanbevelingen af te geven. Hij had in ieder geval goedkoop kunnen inslaan;)
Laatste ...*** 0,837***... 17:39:50 Theor. open 0,837 17:35:10 Bied 0,82 17:40:01 Laat 0,84 17:40:05 Laagste ...***0,512***... 09:00:23 Hoogste ...***0,862***... 15:57:00 Open 0,518 09:00:23 Vorig slot 0,4905 26-05-20 Cum. vol...***9.310.474***... Gem. dagomzet ...***269.348***... Een plus van 70,64%
Ooit voor € 1,- gekocht. En maar zakken, zakken. Gaat het nog wat worden ? Lachen hoor.
voorschoten schreef op 28 mei 2020 09:35 :
Ooit voor € 1,- gekocht.
En maar zakken, zakken.
Gaat het nog wat worden ?
Lachen hoor.
Ja, het kon nog veel lager. Maar het zal het laatste aandeel in de biotechnologie niet zijn, dat ook nog weer veel hoger bleek te kunnen. En dar hopen we dan maar op:)
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee